louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04352257: Bladder and Prostate Sonomorphology in Patients With Symptomatic Benign Prostatic Hyperplasia
Official title: Bladder and Prostate Sonomorphology as a Useful Tool for Detecting Bladder Outlet Obstruction in Patients With Symptomatic Benign Prostatic Hyperplasia
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Benign Prostatic Hyperplasia
Lead sponsor: Kafrelsheikh University
Sponsor class: OTHER
First posted: 2020-04-20
Enrollment: 200
Sex: MALE
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patient more than 50 year old who were presented with Lower urinary tract symptoms.The patients were be subjected to pelvic and transrectal ultrasound.

Brief summary: Bladder and Prostate Sonomorphology in Patients With Symptomatic Benign Prostatic Hyperplasia?

Detailed description: Bladder and Prostate Sonomorphology as a Useful tool for Detecting Bladder Outlet Obstruction in Patients With Symptomatic Benign Prostatic Hyperplasia?

Eligibility criteria: Inclusion Criteria:

male patients with LUTS/BPH prostate size \> 25 g

Exclusion Criteria:

urinary retention diabetes mellitus neurologic deficit LUTS medications prior lower urinary tract surgery concomitant bladder pathology small bladder capacity (\< 150 ml) urethral stricture evident prostate carcinoma.

Primary outcomes:
measure: pelvic and transrectal ultrasound
timeFrame: 18 months
Secondary outcomes:
measure: pelvic and transrectal ultrasound in relation to pressure flow study
timeFrame: 18 months
Other outcomes:
Locations:
city: Kafr Ash Shaykh
country: Egypt
facility: Kafrelsheikh faculty of medicine
state: Kafrelsheikh
Study officials:
affiliation: Lecturer of urology
name: Diaa Eldin Taha, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02039557: Long Term Follow Up Protocol for NiCord®/CordIn™ (Omidubicel) Patients
Official title: Long Term Follow Up for Patients Who Have Received Allogeneic Stem Cell Transplantation of NiCord®/CordIn™, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Patients Transplanted With NiCord/CordIn (Omidubicel)
Lead sponsor: Gamida Cell ltd
Sponsor class: INDUSTRY
First posted: 2014-01-17
Enrollment: 33
Sex: ALL
Minimum age (years): 2
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: NiCord® (ages 12-65)/CordIn™ (ages 2-25) (omidubicel) transplanted patients

Brief summary: This is an observational study that will monitor clinical outcomes of patients who have received a NiCord®/CordIn™ (omidubicel) transplant as part of a GC clinical interventional study and meet the eligibility criteria for this Long Term Follow Up study.


Eligibility criteria: Inclusion Criteria

* Anyone who has received a NiCord®/CordIn™ (omidubicel) transplant, completed study specific follow up, and has signed the consent for this study.

Exclusion Criteria

* None

Primary outcomes:
measure: long term sustained chimerism of NiCord®/CordIn™ (omidubicel) transplantation
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Oakland
country: United States
facility: UCSF Benioff Children's Hospital
state: California
city: Maywood
country: United States
facility: Loyola University, Cardinal Bernardin Cancer Center
state: Illinois
city: Durham
country: United States
facility: Duke University Medical Center
state: North Carolina
city: Durham
country: United States
facility: Duke University Medical Center
state: North Carolina
city: Nashville
country: United States
facility: Vanderbilt
state: Tennessee
city: Utrecht
country: Netherlands
facility: University Medical Center Utrecht
city: Singapore
country: Singapore
facility: National University Cancer Institute
city: Singapore
country: Singapore
facility: Singapore General Hospital
city: Barcelona
country: Spain
facility: University Hospital Vall D'Hebron
city: Valencia
country: Spain
facility: Hospital Universitario La Fe
Study officials:
References:
Clinical trial NCT02482857: Optimal Dose of Acetylsalicylic Acid After Coronary Artery Bypass Grafting
Official title: Optimal Dose of Acetylsalicylic Acid After Coronary Artery Bypass Grafting
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Coronary Artery Bypass Surgery
Stable Angina
Lead sponsor: Karolinska University Hospital
Sponsor class: OTHER
Collaborators: name: Karolinska Institutet
First posted: 2015-06-26
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a single-center, open-label, randomized controlled trial. Patients with stable angina pectoris without use of dual antiplatelet therapy or anticoagulation therapy scheduled for coronary artery bypass grafting (CABG) at Karolinska University Hospital in Stockholm, Sweden will be eligible.

This study investigates in patients having undergone CABG whether increasing the dose or the frequency of acetylsalicylic acid (ASA) treatment improves the efficacy of ASA regarding platelet inhibition compared to the standard dosing for cardiovascular prevention (75 mg once daily) in the first three months after surgery. Patients will be randomly assigned to postoperative ASA dose 75mg once daily, 75mg twice daily or 160 mg once daily. The study dose ASA will be started at hospital discharge and continued of three months. Blood samples for serum thromboxane B2 (TxB2) and other analyses will be taken before surgery, before discharge, and after one and three months. All available data will be collected prospectively. Informed consent will be obtained from patients meeting the inclusion criteria before the initiation of any study-specific procedures.


Eligibility criteria: Inclusion Criteria:

* Stable coronary artery disease
* ≥18 years of age
* Scheduled to undergo elective CABG surgery
* Willing to participate and able to provide informed consent

Exclusion Criteria:

* Intake of drugs other than ASA that are known to influence platelet function, including nonsteroidal anti-inflammatory drugs (NSAIDs, including COX-2 selective anti-inflammatory drugs), GPIIbIIIa inhibitors, clopidogrel, dipyridamole, warfarin or acenocoumarol within 7 days of enrolment
* Hemorrhagic diathesis or known platelet dysfunction
* Chronic renal failure requiring dialysis
* Platelet count outside the 100 000 to 450 000/μL range
* Haemoglobin \< 8g/dl

Primary outcomes:
measure: Serum thromboxane B2
timeFrame: 3 months
Secondary outcomes:
measure: Multiple electrode aggregometry platelet aggregation
timeFrame: 3 months
Other outcomes:
Locations:
Study officials:
affiliation: Karolinska University Hospital
name: Paul Hjemdahl, Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05237557: Impact of an Operating Room Nurse Pre-operative Dialogue in Patients Undergoing Major Visceral Surgery
Official title: Impact of an Operating Room Nurse Pre-operative Dialogue on Anxiety, Satisfaction and Early Postoperative Outcomes in Patients Undergoing Major Visceral Surgery - a Single Center, Open-label, Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Anxiety
Post Operative Pain
Postoperative Nausea
Postoperative Complications
Satisfaction, Patient
Lead sponsor: University of Lausanne Hospitals
Sponsor class: OTHER
First posted: 2022-02-14
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Single center, Open-label, Randomized controlled trial
Primary purpose: SUPPORTIVE_CARE

Brief summary: Single-center, open label, randomized controlled trial of a preoperative nursing dialogue in patient undergoing major visceral surgery aiming in evaluating its impact on patients' anxiety, satisfaction and early postoperative outcomes.


Eligibility criteria: Inclusion Criteria:

* Patient undergoing elective major visceral surgery
* Hospitalization the day before surgery
* Sufficient command of French language

Exclusion Criteria:

* emergency procedures (after unplanned admission)
* inability to obtain informed consent or refusal
* inability to follow intervention

Primary outcomes:
measure: Preoperative anxiety
timeFrame: 5-10 minutes after intervention
Secondary outcomes:
Other outcomes:
Locations:
city: Lausanne
country: Switzerland
facility: Department of Visceral Surgery, University Hospital CHUV, Lausanne
Study officials:
References:
Clinical trial NCT01137357: Probiotics for Reduction Of Markers In Subjects With Allergy
Official title: Probiotics for Reduction Of Markers In Subjects With Allergy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hay Fever
Birch Pollen Allergy
Lead sponsor: Rijnstate Hospital
Sponsor class: OTHER
Collaborators: name: Allergologiepraktijk Arnhem/Radboud/Rijnstate
name: NIZO Food Research
name: Wageningen University
name: Campina Innovation
First posted: 2010-06-04
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In vitro studies reveal immunomodulatory effects of probiotic bacteria that are strain-dependent. Differential immunomodulatory in vitro capacities can not be extrapolated directly to in vivo efficacy. Thus, in vitro screening should be followed by comparative analysis of the selected immunomodulatory probiotic strains in an in vivo setting. Birch pollen allergy is one of the most common forms of respiratory allergy in European countries, and recognized by a Th2-skewed immune system. Five Lactobacillus strains will be evaluated for their immunomodulatory properties in birch pollen sensitive subjects outside the hay fever season. A double-blind placebo-controlled parallel study will be performed in which subjects with a proven birch pollen allergy will consume one of 5 different probiotic yoghurts containing 4 L. plantarum strains and 1 L. casei strain or a placebo yoghurt. Blood samples are collected at the start and after 4 weeks. Immune parameters are determined in serum and peripheral blood mononuclear cell cultures (hPBMC) derived from these subjects.


Eligibility criteria: Inclusion Criteria:

* birch pollen sensitive subjects
* Positive RAST or intracutane skintest
* age 18-50
* signed informed consent form

Exclusion Criteria:

* use of probiotics
* known allergy for pets (home setting)
* use of medication influencing the immune system
* use of antibiotics
* lactose intolerance
* pregnancy
* infection

Primary outcomes:
measure: Il-13 in PBMC after ex-vivo stimulation with birch pollen allergen (Betv1)
Secondary outcomes:
measure: Other cytokines and cell-surface markers in PBMC ex vivo stimulation assay, birch pollen specific IgE, IgG and IgG4 in blood
Other outcomes:
Locations:
city: Arnhem
country: Netherlands
facility: Allergologiepraktijk Arnhem/Radboud/Rijnstate
state: Gelderland
Study officials:
affiliation: Allergologiepraktijk Arnhem/Radboud/Rijnstate
name: A Jansen, Drs
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04469257: SUN LIGHT EXPOSURE AND VITAMIN D LEVEL IN NURSING HOME
Official title: THE EFFECT OF SUN LIGHT EXPOSURE TO THE LEVEL OF VITAMIN D IN THE ELDERLY LIVING IN NURSING HOME
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Nursing Home
Vitamin D Deficiency
Lead sponsor: Tokat Gaziosmanpasa University
Sponsor class: OTHER
First posted: 2020-07-14
Enrollment: 40
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: pretest-posttest randomized controlled experimental study
Primary purpose: SUPPORTIVE_CARE

Brief summary: Objective: The aim of the present study was to determine the effect of nursing interventions and sunlight exposure to reach optimum vitamin D levels by individuals living in nursing homes on vitamin D levels.

Material Method: In the first stage of this two-stage randomized-controlled experimental study with pretest-posttest design conducted in June - August 2018 period in the nursing home in Central Town of Tokat Province, the questionnaire prepared by the researcher, standardized mini mental test, Fitzpatrick skin typing questionnaire and Katz Index of activities of daily living were applied. Intervention (n=20) and control (n=20) groups were established with individuals using simple random method according to age, gender, skin type and vitamin D level. In the second stage, 30-35% of the body surface area of individuals in the intervention group was exposed to sunlight five days a week in July. For the participants in the control group, sunbathing was not offered. 25(OH)D, calcium, parathormone, phosphorus, alkaline phosphatase and albumin levels of all individuals were measured in blood samples taken at the beginning and end of the study. Two-way mixed ANOVA, Mann-Whitney U test, Wilcoxon signed rank test and Chi-square tests were used to evaluate the data.


Eligibility criteria: Inclusion Criteria:

* individuals (25 women and 41 men) who lived in nursing home during June 27, 2018 and August 01, 2018 period
* 60 years and older
* able to perform their daily life activities independently
* agreed to participate in the study

Exclusion Criteria:

* malignancies
* advanced liver and kidney failure
* history of gastric-bowel operation
* skin disease that could prevent sun exposure
* hyperparathyroidism
* malabsorption
* use of drugs that affect the levels of vitamin D, calcium, PTH and phosphorus and albumin

Primary outcomes:
measure: Vitamin D
timeFrame: 5 week
Secondary outcomes:
measure: Parathormone
timeFrame: 5 week
measure: Calicium
timeFrame: 5 week
measure: Phosphorus
timeFrame: 5 week
measure: Alkaline Phosphatase
timeFrame: 5 week
measure: Albumin
timeFrame: 5 week
Other outcomes:
Locations:
city: Tokat
country: Turkey
facility: Tokat Gaziosmanpasa University
Study officials:
References:
Clinical trial NCT04902157: Relationship Between CT- Value With Prognosis in COVID-19 Patients
Official title: Relationship Between CT- Value With Prognosis in COVID-19 Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: COVID-19
Keywords: COVID-19
Lead sponsor: Shahid Beheshti University of Medical Sciences
Sponsor class: OTHER
First posted: 2021-05-26
Enrollment: 60
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: COVID-19 PCR Positive

Brief summary: evaluate the relationship between cycle threshold number with final prognosis in COVID-19 patients

Detailed description: evaluate the relationship between cycle threshold number with final prognosis in COVID-19 patients

Eligibility criteria: Inclusion Criteria:

* COVID-19 PCR positive

Exclusion Criteria:

-

Primary outcomes:
measure: prognosis
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: SBMU
city: Tehran
country: Iran, Islamic Republic of
facility: Nooshin Dalili
Study officials:
References:
Clinical trial NCT00786357: Sleep Enhancement Training Study for Experienced Shiftworkers
Official title: Sleep Enhancement Training Study for Experienced Shiftworkers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Shift-Work Sleep Disorder
Keywords: shift-work
sleep
nurse
relaxation
Lead sponsor: University of California, San Francisco
Sponsor class: OTHER
Collaborators: name: National Heart, Lung, and Blood Institute (NHLBI)
First posted: 2008-11-06
Enrollment: 32
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if a modified version of the Sleep Enhancement Fatigue Reduction Training (SEFRT) system can improve sleep and health-related symptoms and quality of life in experienced shift-working nurses.


Eligibility criteria: Inclusion Criteria:

* English-speaking nurses
* scheduled to work at least 2 consecutive night shifts per week during the next 3 months
* ≥40 years of age
* experiencing disturbed sleep related to night-shift

Exclusion Criteria:

* current diagnosis of sleep disorder or affective illness

Primary outcomes:
measure: actigraphy measures of sleep
timeFrame: 3 months
Secondary outcomes:
measure: subjective measures of sleep and well-being
timeFrame: 3 months
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: University of California, San Francisco
state: California
Study officials:
affiliation: Inner Health, Inc.
name: Christopher R. Alsten, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01800357: Efficacy and Safety of Mildronate for Acute Ischemic Stroke
Official title: Efficacy and Safety of Mildronate for Acute Ischemic Stroke: Study Protocol for a Randomized, Double-blind, Placebo-controlled Phase II Multicenter Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Acute Ischemic Stroke
Keywords: randomized trial
acute ischemic stroke
mildronate
Lead sponsor: Xijing Hospital
Sponsor class: OTHER
First posted: 2013-02-27
Enrollment: 240
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study seeks to evaluate the efficacy and safety of mildronate injection in treating acute ischemic stroke

Detailed description: a randomized, double-blind, placebo-controlled phase II multicenter trial is conducted to evaluate the efficacy and safety of mildronate injection in patients with acute ischemic stroke. patients will be randomized to receive a 14-day treatment of placebo or mildronate (500mg/5ml/each).Primary end-point is the modified Rankin scale at 3 monthes. Secondary end-point is the NIHSS scores and the Barthel index at 8 days and 15days. The safety end-point is defined as the incidence of adverse events, the change of Samples for routine laboratory tests and vital signs. Analysis is by intention to treat.

Eligibility criteria: Inclusion Criteria:

- have a clinical diagnosis of acute ischemic stroke have CT or MRI brain imaging NIHSS scores:5\~22 on the first stage

Exclusion Criteria:

- have other intracranial pathologies are pregnant or nursing have significant drug or alcohol misuse have been in a clinical trial in the past 3 months are unlikely to be available for follow-up have been given thrombolytic therapy or medication forbidden by study protocol have a neurological or psychiatric disease

Primary outcomes:
measure: the modified Rankin scale
timeFrame: 3 months
Secondary outcomes:
measure: NIHSS scores
timeFrame: 8 days
measure: NIHSS scores
timeFrame: 15 days
measure: the Barthel index
timeFrame: 8 days
measure: the Barthel index
timeFrame: 15 days
Other outcomes:
Locations:
city: Xi'an
country: China
facility: the Department of Neurology , Xijing Hospital
state: Shaanxi
Study officials:
affiliation: the Department of Neurology , Xijing Hospital
name: Gang Zhao, MD
role: STUDY_DIRECTOR
affiliation: the Department of Neurology , Xijing Hospital
name: Yi Zhu, MD
role: STUDY_CHAIR
References:
Clinical trial NCT01576926: Evolution of Swallowing in Patients Undergoing Lateral Pharyngoplasty With Preservation Stylopharyngeal Muscle
Official title: Evolution of Swallowing in Patients Undergoing Lateral Pharyngoplasty With Preservation Stylopharyngeal Muscle
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sleep Apnea
Keywords: Sleep apnea, obstructive
Deglutition Disorders
Lead sponsor: Hospital do Servidor Publico Estadual
Sponsor class: OTHER
First posted: 2012-04-13
Enrollment: 1
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with obstructive sleep apnea, indicating the lateral pharyngeal

Brief summary: Evolution of swallowing in patients undergoing lateral pharyngoplasty with preservation stylopharyngeal muscle.

Detailed description: refer patients to the side pharyngoplasty with total preservation of stylopharyngeal muscle and evaluate the total recovery time of swallowing, making a daily assessment.

Eligibility criteria: Inclusion Criteria:

* patients with obstructive sleep apnea with surgical indication

Exclusion Criteria:

* patients with obstructive sleep apnea without surgical indication

Primary outcomes:
measure: Evolution of swallowing in patients undergoing lateral pharyngoplasty with preservation stylopharyngeal muscle
timeFrame: assess progress daily until the end of swallowing dysphagia during 30 days
Secondary outcomes:
measure: Evolution of swallowing in patients undergoing lateral pharyngoplasty with preservation stylopharyngeal muscle
timeFrame: assess progress daily until the end of swallowing dysphagia during 30 days
Other outcomes:
Locations:
city: Sao Paulo
country: Brazil
facility: Hospital Do Servidor Publico Estadual
Study officials:
affiliation: Hopital Do Servidor Público Estadual
name: Jayson Mesti, medical
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05187026: Electrical Patient Reported Outcome of Prostate Cancer RadioTherapy
Official title: Electrical Patient Reported Outcome of Prostate Cancer RadioTherapy
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Prostate Cancer
Keywords: PROM
EPIC-26
electronic
questionnaire
mobile
quality of life
radiation therapy
Lead sponsor: Helsinki University Central Hospital
Sponsor class: OTHER
First posted: 2022-01-11
Enrollment: 300
Sex: MALE
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: - local/locally advanced prostate cancer treated with radiotherapy

Brief summary: This is an observational study where prostate cancer related PROMs (EPIC-26) is collected using two different methods (by paper questionnaires and electronically) and patient experience and preference is asked.

Detailed description: Prostate cancer patients that are treated with radiation therapy for local prostate cancer receive EPIC-26 before treatment and during follow-up. EPIC-26 is collected both traditionally using paper questionnaires and electronically. Patients experience and preference for these are asked.

Eligibility criteria: Inclusion Criteria:

* cT1-4N0M0, gleason 6-10, PSA \< 100, WHO ≤ 2 prostate cancer eligible for radiation therapy
* willing to complete EPIC-26 questionnaires both in paper and electronically
* willing to consent for the study

Exclusion Criteria:

* not able to complete EPIC-26 both in paper and electronically

Primary outcomes:
measure: preference
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
measure: QoL as measured using the validated EPIC-26 questionnaire
timeFrame: through study completion, an average of 1 year
Other outcomes:
Locations:
city: Helsinki
country: Finland
facility: Helsinki University Hospital
state: Uusimaa
Study officials:
affiliation: Helsinki University Central Hospital
name: Antti S Rannikko, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: